Home🔒 SSL Verified
Live Data Status: |E-commerce & Retail
Welcome to the detailed analysis for medicalletter.org. This domain is officially recognized as The Medical Letter, Inc.. According to their official web presence, their primary focus is: "The Medical Letter has provided trusted prescription drug information and drug facts since 1959".
Table of Contents
- Tech Stack
- WordPress
- Link Profile
- Internal Pages: 45Outbound Links: 18
- Localization
- en
6-Month Traffic Trend Estimate
M1
M2
M3
M4
M5
M6
Estimated Market Value
$418,300
Based on domain age, authority, and keyword relevance.
TLD Availability Risk
- medicalletter.comTaken
- medicalletter.netTaken
- medicalletter.orgAvailable
- medicalletter.ioAvailable
- medicalletter.coAvailable
- medicalletter.aiAvailable
Official Contact & Profiles
Content Snippets from medicalletter.org
"Insulin icodec (Awiqli – Novo Nordisk), an ultra-long-acting basal human insulin analog, has been approved by the FDA for once-weekly treatment of type 2 diabetes. Two long-acting insulin analogs are available in the US for once-daily use: glargine and degludec (see Table 1). Insulin icodec has been available in Canada since 2024."
"INSULIN FOR TYPE 2 DIABETES — Many patients with type 2 diabetes eventually require insulin for glycemic control. When adding insulin to other glucose-lowering drugs, a basal insulin is usually the first choice. Continue reading"
"The injectable GIP/GLP-1 receptor agonist tirzepatide (Mounjaro – Lilly), which was approved by the FDA in 2022 for treatment of type 2 diabetes,1 has now been approved to reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events. Tirzepatide is also available as Zepbound for chronic weight management and for treatment of obstructive sleep apnea in adults with obesity.2,3"
"GLP-1 RECEPTOR AGONISTS — The injectable GLP-1 receptor agonists semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) and oral semaglutide (Ozempic, Rybelsus) are also approved for cardiovascular risk reduction in patients with type 2 diabetes. These drugs have reduced the risk of MACE by up to 20% in clinical trials in patients with type 2 diabetes.4"
Key Topics & Focus Areas for medicalletter.org:
Authority Metrics: Score 49/100
Global Reach of Medicalletter
Competitor Analysis for .ORG Domains
By comparing medicalletter.org to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to medicalletter.org.
Frequently Asked Questions
Is medicalletter.org a safe and secure website?
Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.
What is the authority score of medicalletter.org?
As of September 29, 2026, medicalletter.org holds an estimated domain authority score of 89/100 based on our VisitRank tracking algorithms.
What are the top alternatives to medicalletter.org?
You can find the best alternatives and similar sites to medicalletter.org in our explore section, which includes competitors in the E-commerce & Retail sector.
Data Sources & Methodology: DNS telemetry and routing records are resolved via live root servers. Market valuation estimates are computed algorithmically based on proprietary historical indexation multiples and standardized digital asset appraisal methodologies.
Common Misspellings & Typo Domains for medicalletter.org:
mdeicalletter.orgmeicalletter.orgmeedicalletter.orgmadicalletter.orgmedocalletter.orgmedicelletter.orgmedicallatter.orgmedicallettar.orgmwdicalletter.orgmsdicalletter.org